Mobius® ADC Reactor Performance

Antibody-drug conjugates (ADCs) have become an important tool in treating serious diseases, particularly cancers such as breast cancer and non-small-cell lung cancer, due to their ability to precisely target cells and reduce off-target toxicity. ADCs are made up of three main components: a targeting antibody, a cytotoxic payload, and a linker. The linker connects the antibody to the payload and is designed to remain stable in circulation, often releasing the payload after the ADC has entered the intended cells.

The global market for these complex biologics is rapidly expanding, with many ADC drugs in the clinical pipeline and several FDA-approved. As the number of ADC projects increases in the pharmaceutical industry, streamlining development and manufacturing processes will be important for expediting the delivery of new therapies to patients. To meet the industry's growing needs, MilliporeSigma has created a series of single-use ADC reactors in 10 L, 100 L, and 500 L sizes, offering a safer and more efficient production method than traditional mixing systems. Continue reading to learn about these innovative ADC reactors.